text:
VIEWS: 25 PAGES: 25 CATEGORY: Termination Agreement POSTED ON: 3/14/2012
Exhibit 10.29 Confidential Materials omitted and filed separately with the Exhibit Securities and Exchange Commission. Asterisks denote omissions. 10.29 TERMINATION AGREEMENT Dated November 30, 2011 By and Between Idera Pharmaceuticals, Inc. And Merck KGaA concerning the "License Agreement between Idera Pharmaceuticals, Inc. and Merck KGaA" dated December 18, 2007 as amended THIS TERMINATION AGREEMENT (the "Agreement" ) is dated as of November 30, 2011 (the "Effective Date" ) by and between Idera Pharmaceuticals, Inc., a corporation organized under the laws of Delaware having its place of business at 167 Sidney Street, Cambridge, MA 02139, United States ( "Idera" ) and Merck KGaA, a general partnership limited by shares organized under German law having a place of business at Frankfurter Strasse 250, 64293 Darmstadt, Germany ( "Merck" ). Idera and Merck may be referred to herein as a "Party" or, collectively, as "Parties" . RECITALS: WHEREAS Idera and Merck have entered into a license agreement on December 18, 2007 concerning the Field (as defined in the License Agreement) (the "License Agreement" ); WHEREAS Idera and Merck amended the License Agreement as of 12 February 2009; WHEREAS the Parties intend for the rights granted to Merck under the License Agreement to revert back to Idera in accordance with this Agreement; WHEREAS the sponsorship of the Studies (as defined in Article 1.11 below) cannot be transferred from Merck to Idera for regulatory and contractual reasons and as such, the Parties intend for Merck to remain as the sponsor (the "Sponsor" ) of the Studies until their completion; WHEREAS the Parties intend for Merck, as Sponsor, to continue the Merck Activities (as defined in Article 1.7 below) regarding the Studies as set forth in this Agreement; WHEREAS the Parties intend for Merck to have the rights, under Idera's rights, that are required for Merck to conduct and complete the Merck Activities; WHEREAS the Parties intend for Idera to (i) take over the Idera Activities (as defined in Article 1.5 below) and (ii) reimburse Merck for its Third-Party cost for specified Merck Activities, as set forth in this Agreement; WHEREAS the Parties intend for Idera to pay the Milestones (as defined in Article 1.8 below) to Merck according to the terms set forth in this Agreement; WHEREAS the Parties intend for Idera to have rights to use Merck IP under conditions set forth in this Agreement; WHEREAS the transfer of the Program (as defined in Article 1.9 below) shall be as set forth in this Agreement; NOW, THEREFORE, in consideration of the various promises and undertakings set forth herein, the Parties agree as follows: Article 1 DEFINITIONS 1.1 Definitions. Except as otherwise explicitly stated herein, initially capitalized terms used but not otherwise defined herein will have the meanings defined for them in the License Agreement. In addition to the terms defined above and other terms defined in other Articles of this Agreement the following initially capitalized terms have the meanings set forth below for purposes of this Agreement: 1.2 "Alphalytik" means the contract research laboratory Alphalytik Pharmaservice GmbH, which is performing the stability studies set forth in Article 3.5. 1.3 "Business Days" means a day (other than a Saturday or Sunday) when banks are open for business in the city of London, United Kingdom. 1.4 "ICON " means ICON Clinical Research Limited, with its principal executive offices located at South County Business Park, Leopardstown, Dublin 18, Ireland , which is the clinical research organization carrying out the Study 006 on Merck´s behalf. 1.5 "IderaActivities" means the activities to be performed by Idera as set forth in Schedule 1.5. 1.6 "Merck IP" shall mean the intellectual property rights owned or developed by Merck or its Affiliates under the License Agreement, which are further clarified in Section 2.5 below and are set forth in Schedule 1.6. 1.7 "Merck Activities" shall mean the activities to be performed by Merck, as set forth in Schedule 1.5. 1.8 "Milestones" shall mean the milestone payments as set forth in Article 5.2. 1.9 "Program"shall mean the development program for IMO-2055. 1.10 "Sponsor" shall mean Merck KGaA or its Affiliate, EMD Serono, as the case may be. 1.11 "Studies"shall mean the following clinical studies: • Study -005 (Phase I study of PK, PD and safety of IMO-2055 in healthy subjects); • Study -200 (Phase Ib of erlotinib plus bevacizumab and IMO-2055 in patients with NSCLC who have progressed following initial chemotherapy); • Study -007 (Phase Ib of EMD 1201081 in combination with 5-FU/cisplatin and cetuximab in 1st line subjects with r/m SCCHN); • Study -210 (Phase Ib of FOLFIRI plus cetuximab plus IMO-2055 in patients with CRC who have progressed following chemotherapy); and • Study -006 (as defined in Article 1.12 below). 1.12 "Study -006" shall mean the study -006 (Phase II randomized controlled trial exploring efficacy of EMD 1201081 in combination with cetuximab in 2nd Line cetuximab-naive subjects with r/m SCCHN). 1.13 "Trademark"shall mean Merck's trademark IMOxine in certain countries of the world. 1.14 "IMO-2055" shall mean the TLR9 agonist licensed by Idera to Merck under the License Agreement and identified by Idera compound number IMO-2055 and Merck compound number EMD1021081. Article 2 TRANSFER AND GRANT OF RIGHTS 2.1 Termination of Licensed Rights. As of the Effective Date of this Agreement and for the mutual convenience of both Parties, the License Agreement as amended shall be terminated and all rights and obligations granted thereunder shall end, except for those rights and obligations that survive termination according to this Agreement or to Article 10.4(a) of the License Agreement. 2.2 Limited Grant of Rights. Idera hereby grants to Merck the temporary right, under Idera's rights, to complete the conduct of the Studies and Merck Activites, and any activities that may be required by Regulatory Authorities in respect of the Studies and Merck Activities. Such rights shall automatically terminate individually for each of the Studies and the Merck Activities as such are completed. For clarity, if Idera licenses IMO-2055 to a third party before the end of Merck Activities, Idera will ensure that such license does not limit Merck's rights under this Agreement. 2.3 Merck Indemnification. In addition to any indemnification obligations remaining under the License Agreement, Merck shall indemnify, defend and hold Idera and its Affiliates and each of their respective employees, officers, directors, and agents (the "Idera Indemnitees") harmless from and against any and all liability, damage, loss, cost or expense (including reasonable attorneys' fees) to the extent arising out of Third Party claims or suits related to the Merck Activities; provided, however, that Merck's obligations pursuant to this Section 2.4 shall not apply to the extent such claims or suits result from the negligence or willful misconduct of any of the Idera Indemnitees. 2.4 Idera Indemnification. In addition to any indemnification obligations remaining under the License Agreement, Idera shall indemnify, defend and hold Merck and its Affiliates and each of their respective employees, officers, directors, and agents (the "Merck Indemnitees") harmless from and against any and all liability, damage, loss, cost or expense (including reasonable attorneys' fees) to the extent arising out of Third Party claims or suits related to (i) the Idera Activities; and (ii) to any and all of Idera`s or its Affiliates or Third Party activities as regards the Licensed Product after the transfer of the Program; provided, however, that Idera's obligations pursuant to this Section 2.5 shall not apply to the extent such claims or suits result from the negligence or willful misconduct of any of the Merck Indemnitees. As between Idera and Merck, after the Merck Activities are completed, Idera shall be solely responsible for the further research, development and commercialization of the Licensed Product, including but not limited to the use of any information and data generated by Merck under the License Agreement and this Agreement or as a result of its use of the Licensed Product. 2.5 License Grant to Merck IP. Merck has established certain new processes with regard to the formulation and manufacture of the Licensed Product and now possesses certain Merck IP related thereto. Such processes are materially different than those previously established by Idera. As of the Effective Date, Merck also holds the Trademark in certain countries around the World. The new formulation/manufacture process and the Trademark are considered the Merck IP. Subject to Idera's decision under Article 4 to purchase Licensed Product manufactured with Merck IP, Merck hereby grants to Idera the option to take a worldwide, non-exclusive, royalty-bearing license (with a right to sublicense) to the Merck IP, excluding the Trademark, under the conditions set forth in Schedule 10.4 (c) Part I (F) Part II B No. 2 and 4 of the License Agreement. Additionally, Idera shall have the option to acquire a worldwide, exclusive, royalty-bearing license (with a right to sublicense) to the Trademark under the conditions set forth in Schedule 10.4 (c) Part I (G) Part II B No. 3 and 4 of the License Agreement if within [**] Business Days after the Effective Date Idera notifies Merck in writing that it elects to exercise its option. If Idera does not so notify Merck, this option shall expire and Merck shall not be obliged to maintain the Trademark after that. Should Idera elect to use the Trademark, then the financial obligations of maintenance as of the Trademark option exercise shall be carried by Idera. Article 3 RESPONSIBILITIES 3.1 Sponsor of Studies. Merck shall remain the Sponsor of all Studies until finalization of such Studies or until transferred according to Article 3.7. 3.2 Merck Activities. Merck shall be responsible for finalization of the non-clinical studies outlined in Schedule 3.4 and the Studies, for the benefit of Idera. The Merck Activities shall be considered to be fulfilled when the activities listed in Schedule 3.4 have been completed. Merck shall carry out the activities that are listed as Merck Activities in Schedule 1.5 using Commercially Reasonable Efforts. Idera shall be permitted to provide input on the Study 006 and Merck shall reasonably consider Idera's input in carrying out the Merck Activities. The timelines shown in Schedule 3.4 are those that Merck currently considers reasonable. In the event Merck reasonably anticipates that a delay beyond [**] Business Days will occur, Merck will promptly contact Idera and the Parties will reasonably consider a path forward. 3.3 Communication with Regulatory Authorities. Merck shall remain responsible for any and all communication with Regulatory Authorities with respect to the Studies. 3.4 Transfer of Documents. a) In fulfillment of Merck´s obligations under Schedule 10.4(c) A-E of the License Agreement, Merck shall transfer to Idera copies of the documents set forth in Schedule 3.4 in accordance with the timelines indicated therein, with Merck remaining the owner of such documents. If Idera wishes to obtain copies of additional documents that are not covered by Schedule 10.4(c) A-E of the License Agreement, provision of such documents shall be at Merck´s sole discretion and Idera shall bear the reasonable costs for copying and transfer of such documents. Idera may use all documents transferred by Merck and the information contained therein as it sees fit for any of its business purposes, including making press releases related to the data from the Studies. Idera's use of information contained in documents transferred according to this section 3.4(a) shall be at its own risk and responsibility. For clarity, the aforementioned right to use documents does not include a license to use the Merck name, logo, trademark or other Merck proprietary mark, or any Merck IP. b) If needed for the advancement of IMO-2055, Merck agrees to provide Idera or its licensee with a letter to be submitted to a Regulatory Authority permitting cross reference with Merck's or its Affiliate's existing IND application and its ex-USA equivalent(s) for IMO-2055. The foregoing does not imply an obligation on Merck to maintain or not to terminate such application(s), unless such has been agreed in writing between Merck and Idera. 3.5 CMC Activities. As part of winding-down the Studies and the manufacturing activities related thereto, Merck will discontinue all activities related to drug substance-, formulation- and analytical development of all Compounds and Follow-on Compounds. Discontinuing formulation development includes Merck's short term stability studies after 9-months stability data become available from Alphalytik. Upon Idera´s request, and subject to Idera´s willingness to take on all subsequent costs and duties associated with such stability studies, Merck is willing to provide reasonable assistance to Idera to enable continuation of the ongoing stability studies beyond the 9-month timepoint. Idera will inform Merck within [**] days after the Effective Date if it wants to assume the responsibility of conducting the stability studies beyond 9 months. In any event, Merck shall not be liable to Idera for any failure of Idera to enter into a contract with Alphalytik. Furthermore, Merck´s assistance will be limited to reasonable efforts to establish contact and mediate a handover within [**] months following the Effective Date, but shall not include any continuation of technical activities such as laboratory work. 3.6. Idera Activities. Idera shall carry out the activities that are listed as Idera Activities in Schedule 1.5 using Commercially Reasonable Efforts. 3.7 Transfer of Sponsorship. If at any time while Merck is conducting Study -006, Idera or a licensee of Idera has the ability to assume the role as sponsor of such trial and it is feasible from a regulatory perspective to transfer sponsorship, then Idera, in its sole discretion, may contact Merck and the Parties will work reasonably and diligently to implement the transfer of such sponsorship, with Idera or its licensee assuming all future, third-party costs for conducting the Study -006 beginning on the effective date of the sponsorship transfer. For clarity, Idera or its licensee shall cover any additional costs, including but not limited to Merck's internal costs, caused by the transfer of sponsorship. 3.8 Publication(s). For any publication or press release related to any of the Studies, the publishing Party agrees to provide the non-publishing Party with advance notice of [**] Business Days for publications and [**] Business Days for press releases. The non-publishing Party may review and comment on such publication or press release during the corresponding advance notice period and the publishing Party agrees to reasonably consider such comments in preparing the final version of the publication or press release. Article 4 SUPPLY OF LICENSED PRODUCT As set forth in Schedule 10.4 (c) Part I (E) of the License Agreement, Merck agrees to supply to Idera , upon request and payment, and for a period of up to [**] months following the Effective Date, with its available and existing stock of Compounds, Follow-on Compounds, and Licensed Product. A list of available Compounds, Follow-on Compounds, and Licensed Product and the fully burdened cost thereof (but excluding the [**]% mark up due under Schedule 10.4 (c) (E) that is applicable to delivery of Compounds, Follow-on Compounds or Licensed Product) is attached to this Agreement as Schedule 4. Idera shall be able to obtain any or all of the listed stocks and if purchased, Merck shall provide Idera or its designee with the Merck IP (excluding the Trademark) with respect to the manufacture of each such Compound, Follow-on Compound or Licensed Product. The Parties recognize and agree that certain Compounds, Follow-on Compounds, and Licensed Products were manufactured without using Merck IP and only those Compounds, Follow-on Compounds, and Licensed Products manufactured using Merck IP shall be subject to the Reverse Royalty set forth in Section 5.4. The Parties recognize and agree that Idera may, without relying upon or using any Merck IP, develop new manufacturing processes that may be similar or the same as the manufacturing processes included in the Merck IP. If Idera develops such manufacturing process without relying upon or using any Merck IP, then no Reverse Royalties will be due on Compounds, Follow-on Compounds, or Licensed Products manufactured by Idera with that manufacturing process. For clarity, if Idera purchases Compound, Follow-on Compound or Licensed Product manufactured with Merck IP, Idera is obliged to take a license to Merck IP and the Reverse Royalities in Article 5.3 will be due if such Merck IP is used for Compound, Follow-on Compound or Licensed Product. Merck will destroy those materials listed in Schedule 4 not purchased by Idera within a reasonable time following [**] months of the Effective Date, and Idera´s option to take a worldwide license to the Merck IP, excluding the Trademark, will expire. Article 5 PAYMENTS 5.1 CRO Costs. As consideration for the early return of rights and achievements under the License Agreement, Idera agrees to reimburse Merck for its Third-Party contract research organization, ICON, costs to a maximum of €1,816,391 for the Study 006. The reimbursement schedule is as set forth below: Monthly reimbursements of €165,126 to be invoiced by Merck to Idera beginning 1 st March 2012 and ending 1 st December 2012 (10 invoices). Upon completion of all Merck Activities, other than publications (1 invoice) €165,131. Merck shall be responsible for any costs for Study -006 in excess of €1,816,391, unless such excess costs are the result of additional work requested by Idera and agreed upon in writing by Merck. In which case, Idera shall be responsible for paying those excess external and Merck internal costs of additional work that Merck agreed to perform. Merck shall provide Idera with an invoice (i) on the 1 st day of the corresponding month for the monthly payments and (ii) within thirty days after completing all of the Merck Activities for the final payment. Idera shall pay invoiced amounts within [**] days after receipt of an invoice from Merck to the bank account specified in such invoice. Merck shall remain responsible for any costs in excess of those identified in this Article 5.1. 5.2 Milestones. As consideration for Merck's achievement under the License Agreement, Idera shall pay, or cause to be paid to Merck, a one-time payment for the achievement by Idera of each of the milestone events set forth below (the "Milestones" ). Idera shall promptly notify Merck in writing of the occurrence of any such Milestone event and Merck shall subsequently provide Idera with an invoice for the amount due. Such Milestone payments shall accrue on the achievement of the applicable milestone event and shall be paid by Idera within [**] days after receiving Merck's invoice for such Milestone event. Upon partnering of IMO-2055 (whether with or without other compounds) €1,000,000 Upon Initiation of any Phase II or Phase III Clinical Trial for IMO-2055 €1,000,000 Upon Regulatory submission of IMO-2055 in any country €1,000,000 The partnering of IMO-2055 Milestone shall be accomplished when an agreement relating to IMO-2055 is signed between Idera and any Third Party. 5.3 Reverse Royalties. Part II of Schedule 10.4 (c) of the License Agreement shall be terminated as regards Part II A (the "Licensor First Commercial Sale" milestone) and Part II B No. 1 (Royalty Payments as regards the use of clinical data). Reverse Royalties as set forth in Schedule 10.4 (c) Part II No. 2, 3 and 4 shall be due for Idera's, its Affiliates, or its sublicensee's use of the Merck IP. 5.4 Late Payments. All payments under this Agreement shall earn interest from the date due until paid at a rate per annum of [**] percent ([**]%). 5.5 Taxes . All payments shall be made without any deductions . However, if applicable law or regulations require Idera to withhold taxes on such payments, Idera may deduct such taxes; provided, however, that, Idera shall (i) promptly notify Merck of such requirement, (ii) remit such amount to the proper tax authorities and (iii) provide Merck with the necessary tax receipts in a timely manner. Provided that Merck cooperates with Idera in benefiting from the reduced withholding tax rate set forth in the Double Taxation Convention existing between Germany and the USA, the deductions may not exceed the withholding tax rate mentioned in the Double Taxation Convention. Any additional taxes, duties and other deductions shall have to be borne by Idera. It is understood and agreed between the Parties that any amounts mentioned under this Agreement and to be paid by Idera to Merck are exclusive of any value added or similar tax. If any such tax is imposed upon any payments made by Idera under this Agreement, Idera shall pay such tax to Merck in addition to the amount mentioned under this Agreement upon reception of a proper tax invoice from Merck where any value added tax amount is shown separately. Article 6 CONFIDENTIALITY 6.1 Confidentiality Obligations . Each Party agrees that such Party shall, and shall ensure that its Affiliates and their respective officers, directors, employees and agents shall, keep completely confidential and not publish or otherwise disclose and not use for any purpose except as expressly permitted hereunder any Confidential Information disclosed to it by the other Party pursuant to this Agreement. The foregoing obligations shall not apply to any Confidential Information disclosed by a Party hereunder to the extent that the receiving Party can demonstrate that such Confidential Information: (a) was already known to the receiving Party or its Affiliates, other than under an obligation of confidentiality, at the time of disclosure; (b) was generally available to the public or otherwise part of the public domain at the time of its disclosure to the receiving Party; (c) became generally available to the public or otherwise part of the public domain after its disclosure and other than through any act or omission of the receiving Party in breach of this Agreement; (d) was subsequently lawfully disclosed to the receiving Party or its Affiliates by a Third Party without an obligation of confidentiality other than in contravention of a confidentiality obligation of such Third Party to the disclosing Party; or (e) was developed or discovered by employees or agents of the receiving Party or its Affiliates who had no access to the Confidential Information of the disclosing Party. Notwithstanding the above obligations of confidentiality and non-use, a Party may disclose information to the extent that such disclosure is reasonably necessary in connection with: (i) filing or prosecuting patent applications; (ii) prosecuting or defending litigation; (iii) conducting pre-clinical studies or Clinical Trials; (iv) seeking Regulatory Approval of the Licensed Product in the Field; (v) seeking advice from business, legal and financial advisors, on the condition that such business, legal and financial advisors agree to be bound by confidentiality and non-use obligations at least as strict as those contained in this Agreement; or (vi) complying with applicable Law, including securities Law and the rules of any securities exchange or market on which a Party's securities are listed or traded. In making any disclosures set forth in clauses (i) through (vi) above, the disclosing Party shall, where reasonably practicable, give such advance notice to the other Party of such disclosure requirement as is reasonable under the circumstances and will use its reasonable efforts to cooperate with the other Party in order to secure confidential treatment of such Confidential Information required to be disclosed. In addition, in connection with any permitted filing by either Party of this Agreement with any Governmental Body, including but not limited to the U.S. Securities and Exchange Commission, the filing Party shall endeavor to obtain confidential treatment of economic, trade secret information and such other information as may be requested by the other Party, and shall provide the other Party with the proposed confidential treatment request with reasonable time for such other Party to provide comments, and shall include in such confidential treatment request all reasonable comments of the other Party. Notwithstanding any confidentiality provisions of the License Agreement or this Agreement, Idera shall have the right to use all data and information arising from the Studies without any confidentiality obligations to Merck or its Affiliates. For clarity, this does not allow for the use of Merck name , trademark, trade name and/or logo or that of any Merck Affiliate unless other provisions of this Agreement allow for it. 6.2 Press Releases and Disclosure . Upon execution of this Agreement, Idera shall have the right to issue the press release attached hereto as Schedule 6.2 . Subject to the foregoing sentence, no other disclosure of the existence, or the terms, of this Agreement may be made by either Party, and neither Party shall use the name, trademark, trade name or logo of the other Party, its Affiliates or their respective employees in any publicity, promotion, news release or disclosure relating to this Agreement or its subject matter, without the prior express written permission of the other Party, except as may be required by Law. Article 7 REPRESENTATION AND WARRANTY 7.1 Representations and Warranties . Each Party represents and warrants to the other Party that, as of the Effective Date: (a) such Party is duly organized and validly existing under the Laws of the jurisdiction of its incorporation or organization; (b) such Party has taken all action necessary to authorize the execution and delivery of this Agreement and the performance of its obligations under this Agreement; (c) this Agreement is a legal and valid obligation of such Party, binding upon such Party and enforceable against such Party in accordance with the terms of this Agreement, except as enforcement may be limited by applicable bankruptcy, fraudulent conveyance, insolvency, reorganization, moratorium and other Laws relating to or affecting creditors' rights generally and by general equitable principles. The execution, delivery and performance of this Agreement by such Party does not conflict with, breach or create in any Third Party the right to accelerate, terminate or modify any agreement or instrument to which such Party is a party or by which such Party is bound, and does not violate any Law of any Governmental Body having authority over such Party; (d) such Party has all right, power and authority to enter into this Agreement, to perform its obligations under this Agreement; and (e) no consent by any Third Party or Governmental Body is required with respect to the execution and delivery of this Agreement by such Party or the consummation by such Party of the transactions contemplated hereby. [**]. 7.2 No Warranty . EXCEPT AS OTHERWISE EXPRESSLY SET FORTH IN THIS AGREEMENT, NEITHER PARTY HERETO MAKES ANY REPRESENTATION AND EXTENDS NO WARRANTY OF ANY KIND, EITHER EXPRESS OR IMPLIED. Article 8 MISCELLANEOUS PROVISIONS 8.1 Relationship of the Parties . Nothing in this Agreement is intended or shall be deemed to constitute a partnership, agency, joint venture or employer-employee relationship between the Parties. 8.2 Assignment. (a) Idera may assign this Agreement, in whole or in part, to any Third Party without the consent of Merck. Idera shall give written notice to Merck promptly following any such assignment. (b) Merck may assign this Agreement, in whole or in part, to any Affiliate or Third Party without the consent of Idera. Merck shall give written notice to Idera promptly following any such assignment. (c) No assignment under this Article 13.2 shall relieve the assigning Party of any of its responsibilities or obligations hereunder and provided, further, that as a condition of such assignment, the assignee shall agree to be bound by all obligations of the assigning party hereunder. (d) This Agreement shall be binding upon the successors and permitted assigns of the Parties. (e) Any assignment not in accordance with this Article 8.2 shall be void. 8.3 Performance by Affiliates . Merck shall have the right to have any of its obligations hereunder performed, or its rights hereunder exercised, by, any of its Affiliates and the performance of such obligations by any such Affiliate(s) shall be deemed to be performance by Merck; provided, however, Merck shall be responsible for ensuring the performance of its obligations under this Agreement and that any failure of any Affiliate performing obligations of Merck hereunder shall be deemed to be a failure by Merck to perform such obligations. 8.4 Further Actions . Each Party agrees to execute, acknowledge and deliver such further instruments and to do all such other acts as may be necessary or appropriate in order to carry out the purposes and intent of this Agreement. 8.5 Accounting Procedures . Each Party shall calculate all amounts hereunder and perform other accounting procedures required hereunder and applicable to it in accordance with either, as applicable (a) United States generally accepted accounting principles (US GAAP) or (b) International Financial Reporting Standards (IFRS), whichever is normally used by such Party to calculate its financial position, and in each case consistently applied by such Party. 8.6 Force Majeure . Neither Party shall be liable to the other for failure or delay in the performance of any of its obligations under this Agreement for the time and to the extent such failure or delay is caused by acts of God, earthquake, riot, civil commotion, terrorism, war, strikes or other labor disputes, fire, flood, failure or delay of transportation, default by suppliers or unavailability of raw materials, governmental acts or restrictions or any other reason which is beyond the control of the respective Party. The Party affected by force majeure shall provide the other Party with full particulars thereof as soon as it becomes aware of the same (including its best estimate of the likely extent and duration of the interference with its activities), and will use Commercially Reasonable Efforts to overcome the difficulties created thereby and to resume performance of its obligations hereunder as soon as practicable. 8.7 No Trademark Rights . No right, express or implied, is granted by this Agreement to a Party to use in any manner the name or any other trade name or trademark of the other Party in connection with the performance of this Agreement or otherwise. 8.8 Entire Agreement of the Parties; Amendments . This Agreement and the schedules and exhibits hereto constitute and contain the entire understanding and agreement of the Parties respecting the subject matter hereof and cancel and supersede any and all prior negotiations, correspondence, representations, assurances, promises, understandings and agreements between the Parties, whether oral or written, regarding such subject matter. No waiver, modification or amendment of any provision of this Agreement shall be valid or effective unless made in a writing referencing this Agreement and signed by a duly authorized officer of each Party. 8.9 Captions. The captions to this Agreement are for convenience only, and are to be of no force or effect in construing or interpreting any of the provisions of this Agreement. 8.10 Governing Law; Jurisdiction . This Agreement shall be governed by and interpreted in accordance with English law, excluding application of any conflict of laws principles that would require application of the Law of any other jurisdiction. The courts of England are to have exclusive jurisdiction to settle any dispute arising out of or in connection with this Agreement. Any proceedings, suit or action arising out of or in connection with this Agreement ("Proceedings" ) shall therefore be brought in the English courts. Each Party agrees that this jurisdiction agreement is irrevocable and that it is for the benefit of the other Party. Each Party irrevocably waives (and irrevocably agrees not to raise) any objection, on the ground of forum non conveniens or on any other ground, to the taking of Proceedings in the English courts. Each Party also irrevocably agrees that a judgment against it in Proceedings brought in the English courts shall (provided there is no appeal pending or open) be conclusive and binding upon it and may be enforced in any other jurisdiction. 8.11 Notices and Deliveries . Any notice, request, approval or consent required or permitted to be given under this Agreement shall be in writing and shall be deemed to have been sufficiently given if delivered in person, transmitted by facsimile (receipt verified) or by express courier service (signature required) to the Party to which it is directed at its address or facsimile number shown below or such other address or facsimile number as such Party shall have last given by notice to the other Party. If to Merck, addressed to: Merck KGaA Frankfurter Strasse 250 64293 Darmstadt, Germany Attn: Merck Serono Legal Department Facsimile: 49-6151-72-2373 If to Idera, addressed to: Idera Pharmaceuticals, Inc. 167 Sidney Street Cambridge, MA 02139 Attention: Chief Executive Officer Facsimile: (617) 679-5592 With a copy to: Wilmer Cutler Pickering Hale and Dorr LLP 60 State Street Boston, MA 02109 Attention: David E. Redlick, Esq. Facsimile: (617) 526-5000 8.12 Waiver . A waiver by either Party of any of the terms and conditions of this Agreement in any instance shall not be deemed or construed to be a waiver of such term or condition for the future, or of any other term or condition hereof. All rights, remedies, undertakings, obligations and agreements contained in this Agreement shall be cumulative and none of them shall be in limitation of any other remedy, right, undertaking, obligation or agreement of either Party. 8.13 Rights Of Third Parties. The Parties to this Agreement do not intend that any term of this Agreement shall be enforceable by virtue of the Contract (Rights of Third Parties) Act 1999 or otherwise by any Person who is not a Party to this Agreement. 8.14 Severability . When possible, each provision of this Agreement will be interpreted in such manner as to be effective and valid under applicable Law, but if any provision of this Agreement is held to be prohibited by or invalid under applicable Law, such provision will be ineffective only to the extent of such prohibition or invalidity, without invalidating the remainder of this Agreement. The Parties shall make a good faith effort to replace the invalid or unenforceable provision with a valid one that in its economic effect is most consistent with the invalid or unenforceable provision. 8.15 Counterparts . This Agreement may be executed in one or more counterparts, each of which will be deemed an original, and all of which together will be deemed to be one and the same instrument. A facsimile copy of this Agreement, including the signature pages, will be deemed an original. I N W ITNESS W HEREOF , the Parties have caused this Agreement to be executed and delivered by their respective duly authorized officers as of the Effective Date, each copy of which shall for all purposes be deemed to be an original. IDERA PHARMACEUTICALS, INC. MERCK KGaA By /s/ Sudhir Agrawal By /s/ Dr. Jörn-Peter Halle Name: Sudhir Agrawal Name: Dr. Jörn-Peter Halle Title: President and CEO Title: Vice President, Head Global Product Unit Oncology i.V. By By /s/ Dr. Simone Heitz Name: Name: Dr. Simone Heitz Title: Title: Corporate Counsel Schedule 1.6 Merck Intellectual Property Rights • Know-how with regard to the formulation and manufacture of the Licensed Product that was generated by Merck under the License Agreement (API Development Report from Avecia); and • Trademark IMOxine. Schedule 1.5 Merck Activities and Idera Activities Assignment of activities to Idera for EMR200068-006 Task List Merck Idera Activities for main (primary) study report Project Management Activities : ICON supervision [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] Site Management [**] [**] [**] [**] [**] [**] [**] Newsletters [**] [**] [**] [**] Interaction with HA - FDA (ROW fully outsourced to ICON) [**] [**] [**] [**] [**] [**] [**] [**] [**] Study documents [**] [**] [**] [**] [**] [**] [**] [**] [**] Medical Management [**] [**] [**] [**] [**] [**] [**] [**] [**] Safety activities [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] Data Management [**] [**] [**] [**] [**] [**] [**] [**] [**] Biostatistics [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] Medical Writing [**] [**] [**] [**] [**] [**] [**] After cut off date [**] / activities linked to patients remaining in the study Project Management Activities ICON supervision [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] Interaction with HA - FDA (ROW fully outsourced to ICON) [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] TMF [**] [**] [**] [**] [**] [**] [**] [**] [**] Medical Management [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] Safety activities [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] Data management [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] Medical Writing [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] Schedule 3.4: Transfer Plan IMO-2055 to Idera Data / documents Transfer Timelines Clinical studies Study -005 (randomized, Phase I study of PK, PD and safety of IMO-2055 in healthy subjects) [**] [**] [**] [**] [**] [**] Study -200 (Phase Ib or erlotinib plus bevacizumab and IMO-2055 in patients with NSCLC who have progressed following initaial chemotherapy) [**] [**] [**] [**] [**] [**] Study -007 (Phase Ib of EMD 1201081 in combination with 5-FU/cisplatin and cetuximab in 1st line subjects with r/m SCCHN) [**] [**] [**] [**] Study -210 (Phase Ib of FOLFIRI plus cetuximab plus IMO-2055 in patients with CRC who have progressed following chemotherapy) [**] [**] [**] [**] Study -006 (Phase II randomized controlled trial exlporing efficacy of EMD 1201081 in combination with cetuximab in 2nd L cetuximab-naive subjects with r/m SCCHN) [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] Investigator Brochure (Merck Serono updates) [**] [**] [**] [**] FDA/EMA/Competent Authorities [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] General and Safety Pharmacology [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] Toxicology [**] [**] [**] [**] [**] [**] [**] [**] Drug Metabolism and Pharmacokinetics [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] Biomarker [**] [**] [**] [**] Pharmacology [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] Drug Substance [**] [**] [**] [**] Drug Product [**] [**] [**] [**] [**] [**] All records recently received from Idera (unless local destruction has been agreed) following formal termination of LA CONFIDENTIAL / DRAFT – FOR DISCUSSION PURPOSES ONLY! Schedule 4 Inventory of EMD1201081 (IMO-2055) at Merck, status November 10, 2011 Drug Product Batch No. Amount (vials) Costs/vial (fully Manufacturing date Re-test date Comment loaded) [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] Drug Substance / API Batch No. Amount (g) Costs/g Manufacturing date Release status Comment [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] 22 CONFIDENTIAL / DRAFT – FOR DISCUSSION PURPOSES ONLY! Schedule 6.2 Press Release Idera Pharmaceuticals Regains Global Rights to IMO-2055 in Oncology from Merck KGaA - Phase 2 Data Anticipated in Second Quarter of 2012- CAMBRIDGE, Mass. Nov. XX, 2011. Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today announced that it has regained global rights to IMO-2055, an agonist of Toll-like Receptor (TLR) 9, as part of an agreed-upon termination of its oncology collaboration with Merck KGaA. During the collaboration, Merck KGaA, Darmstadt, Germany, conducted Phase 1 trials of IMO- 2055 in several cancer indications and has an ongoing randomized Phase 2 trial of IMO-2055 in combination with Erbitux ® in patients with squamous cell cancer of the head and neck (SCCHN). As previously announced, in July 2011 Merck had informed Idera that it would not continue clinical development of IMO-2055 beyond completing the ongoing Phase 2 trial in SCCHN. "We believe the potential of IMO-2055 immunotherapy is in combination with targeted anti-cancer agents. Under our termination agreement with Merck KGaA, Merck KGaA will continue to conduct the ongoing Phase 2 trial in patients with SCCHN and Idera will have rights to the data, as well as to the data from Phase 1 trials conducted in other cancer indications. We believe that regaining our rights to IMO-2055, as well as the rights to the clinical data, will provide us greater flexibility and control in the clinical development of IMO-2055 and the opportunity to pursue new business collaborations," commented Sudhir Agrawal, D Phil, Chairman and Chief Executive Officer of Idera. "We appreciate the efforts made by the Merck KGaA team members in significantly advancing this program." Idera expects data from the following clinical trials with IMO-2055 clinical to be available in the near-term: • APhase 1b clinical trial of IMO-2055 in combination with Tarceva ® and Avastin ® in patients with advanced non- small cell lung cancer (NSCLC). • The NSCLC Phase 1b clinical trial evaluated four dose levels of IMO-2055 in combination with Tarceva ® and Avastin ® . Thirty-six patients have been recruited in this trial and data analysis is ongoing. • A Phase 1b clinical trial of IMO-2055 in combination with Erbitux ® and FOLFIRI (5-fluorouracil/leucovorin/irinotecan) in patients with metastatic colorectal cancer (CRC). • The CRC Phase 1b clinical trial evaluated three dose levels of IMO-2055 in combination with Erbitux ® and FOLFIRI. Twenty-two patients have been recruited and data analysis is ongoing. • A randomized Phase 2 clinical trial of IMO-2055 in combination with Erbitux ® versus Erbitux alone as a second-line treatment in patients with recurrent and/or metastatic SCCHN. • The design of the Phase 2 study provides for the enrollment of 104 patients, 52 in each of the two arms. Crossover of patients from Erbitux alone to IMO-2055 in combination with Erbitux is permitted under specified circumstances. The primary endpoint of the trial is progression-free survival. This study is fully enrolled and patient treatment and follow-up are ongoing. 23 CONFIDENTIAL / DRAFT – FOR DISCUSSION PURPOSES ONLY! Merck KGaA has conducted additional clinical trials of IMO-2055 including: • APhase 1 trial of IMO-2055 in combination with Erbitux, cisplatin, and 5-fluorouracil for the first-line treatment of SCCHN. In this trial, treatment with IMO-2055 plus cisplatin/5-fluorouracil and Erbitux was associated with increased neutropenia and electrolyte imbalances as compared to a clinical trial of cisplatin/5-fluorouracil and Erbitux (Vermorken J, et al. NEJM 2008; 359:1116). This study was terminated by Merck KGaA. • A Phase 1 trial in healthy subjects to evaluate safety and dose-dependent pharmacokinetics and pharmacodynamics of IMO-2055 after three weekly doses by subcutaneous or intravenous administration. Idera Pharmaceuticals entered into its worldwide licensing and collaboration agreement with Merck KGaA, Darmstadt, Germany in December 2007 for the research, development and commercialization of Idera's Toll-like Receptor 9 (TLR9) agonists, including IMO-2055, for the potential treatment of certain cancers, excluding cancer vaccines. As part of the agreement between Idera and Merck KGaA as to the termination of the collaboration, Idera has regained all rights for developing TLR9 agonists for the treatment of cancer, including all rights to IMO-2055 and any follow-on TLR9 agonists, and rights to data created under and during the collaboration. Merck KGaA has decided to complete the ongoing Phase 2 trial of IMO-2055 in SCCHN. Idera has agreed to reimburse approximately €1.8 million of Merck KGaA's expenses during the course of the ongoing Phase 2 trial, which the Company expects to pay over the course of approximately twelve months starting in March 2012. Idera has also agreed to pay to Merck KGaA milestone payments of €1 million each upon entering into any future partnership for IMO-2055, upon initiating the next clinical trial of IMO-2055 that is a Phase 2 or Phase 3 clinical trial, and upon the regulatory submission of IMO- 2055 in any country. About Idera Pharmaceuticals, Inc. Idera Pharmaceuticals applies its proprietary Toll-like Receptor (TLR) drug discovery platform to create immunomodulatory drug candidates. The Company's TLR-targeted candidates are being developed to treat autoimmune and inflammatory diseases, cancer, and for use as vaccine adjuvants. Additionally, the Company is advancing its gene-silencing oligonucleotide (GSO) technology for the purpose of inhibiting the expression of disease-promoting genes. For more information, visit http://www.iderapharma.com . Idera Forward Looking Statements This press release contains forward-looking statements concerning Idera Pharmaceuticals, Inc. that involve a number of risks and uncertainties. For this purpose, any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "estimates," "intends," "should," "could," "will," "may," and similar expressions are intended to 24 CONFIDENTIAL / DRAFT – FOR DISCUSSION PURPOSES ONLY! identify forward-looking statements. There are a number of important factors that could cause Idera's actual results to differ materially from those indicated by such forward-looking statements, including whether products based on Idera's technology will advance into or through the clinical trial process on a timely basis or at all and receive approval from the United States Food and Drug Administration or equivalent foreign regulatory agencies; whether, if the Company's products receive approval, they will be successfully distributed and marketed; whether the Company's collaborations will be successful; whether Idera's cash resources will be sufficient to fund the Company's operations; and such other important factors as are set forth under the caption "Risk Factors" in Idera's Quarterly Report on Form 10-Q for the quarter ended September 30, 2011 which important factors are incorporated herein by reference. Idera disclaims any intention or obligation to update any forward-looking statements. SOURCE: Idera Pharmaceuticals, Inc. Idera Pharmaceuticals, Inc. Lou Arcudi, 617-679-5517 email@example.com or MacDougall Biomedical Communications Chris Erdman, 781-235-3060 email@example.com 25
Pages to are hidden for
"Termination Agreement - IDERA PHARMACEUTICALS, - 3-14-2012"Please download to view full document


text:
Dario Borghino
Researchers at the University of Queensland, Australia claim to have simulated the behavior of a single photon traveling back in time and interacting with an older version of itself, in an effort to investigate how such a particle would behave. Their results suggest that, under such circumstances, the laws of quantum mechanics would stretch to become even more bizarre than they already are. Read More
If you've ever felt like pampering your eyeglasses but never knew how, this one may be for you. Swiss startup Cliris SA has taken to Kickstarter to fund the development of Cliris, a sleek-looking, automatic eyewear cleaner that uses ultrasound technology and a biodegradable solution to clean, disinfect, anti-fog treat, dry and (optionally) scent your spectacles in only four minutes. Read More
Researchers at the University of California, Riverside have developed a silicon anode that would allow us to charge lithium-ion batteries up to 16 times faster than is currently possible. The new design relies on a three-dimensional, cone-shaped cluster of carbon nanotubes that could also result in batteries that hold about 60 percent more charge while being 40 percent lighter. Read More
On June 12th, the FIFA 2014 World Cup in Brazil will be kicked off by a paralyzed person using a highly innovative brain-controlled robotic exoskeleton. This feat is being carried out as a demonstration of the current state-of-the art in assisted mobility technology, as the researchers involved – part of the "Walk Again Project" – work toward refining their invention. Read More
Researchers at the University of Toronto have manufactured and tested a new type of colloidal quantum dots (CQD), that, unlike previous attempts, doesn't lose performance as they keep in contact with oxygen. The development could lead to much cheaper or even spray-on solar cells, as well as better LEDs, lasers and weather satellites. Read More
A survey conducted by astronomers at Cornell University has taken into account the characteristics of 637 known exoplanets and elaborated a Biological Complexity Index (BCI) to assess the relative probability of finding complex life on them. Their data supports the view that as many as one hundred million planets scattered around the Milky Way, and perhaps more, could support life beyond the microbial stage. Read More
Researchers at the University of California, Riverside have developed a new graphene-based supercapacitor that uses a nanoscale architecture to double its energy and power performance compared to commercially-available alternatives. This breakthrough is another important step toward making supercapacitors viable for use in fast-charging, high-performance electric cars and personal electronics. Read More
A newly-released picture taken by the Hubble Telescope is adding more color to the Hubble Ultra Deep Field (HUDF) image by detecting thousands of galaxies in the ultraviolet spectrum. The study, called the Ultraviolet Coverage of the Hubble Ultra Deep Field (UVUDF), directly imaged stars and other celestial bodies that would have been impossible to observe on the ground, and gives astronomers critical information that will prove useful as the launch of the more powerful James Webb Space Telescope approaches. Read More
Researchers at the California Institute of Technology are developing a disruptive manufacturing process that combines nanoscale effects and ad-hoc architectural design to build new supermaterials from the ground up. The materials can be designed to meet predetermined criteria such as weighing only a tiny fraction of their macroscopic counterpart, displaying extreme plasticity, or featuring outstanding mechanical strength. Read More
Researchers at the University of Arizona and the University of Connecticut have developed a technology for augmented reality devices that superimposes data over three dimensions rather than two. The technique makes the user experience much more seamless and vastly reduces eye strain, making AR devices more attractive for long-term use. Read More
- Features
- Reviews
- Aircraft
- Architecture
- Around The Home
- Automotive
- Bicycles
- Children
- Computers
- Digital Cameras
- Electronics
- Environment
- Games
- Good Thinking
- Health and Wellbeing
- Holiday Destinations
- Home Entertainment
- Inventors and Remarkable People
- Laptops
- Marine
- Medical
- Military
- Mobile Technology
- Motorcycles
- Music
- Outdoors
- Pets
- Robotics
- Science
- Space
- Sports
- Telecommunications
- Urban Transport
- Wearable Electronics
- 2014 Action Camera Comparison Guide
- 2014 Smartwatch Comparison Guide
- 2014 Windows 2-in-1 Comparison Guide
- 2014 Smartphone Comparison Guide
- 2014 Full Frame DSLR Comparison Guide
- 2014 Tablet Comparison Guide
- 2014 Superzoom Camera Comparison Guide
- 2014 iPad Comparison Guide
- 2014 Entry-Level to Enthusiast DSLR Comparison Guide
- 2014 Small Compact Camera Comparison Guide

subset: commoncrawl


text:
Reader comments are listed below. Comments are currently closed and new comments are no longer being accepted.
Brown should keep the momentum. Voters are fickle the willingness to absorb painful adjustments last only so long. Then you'll lose them voting for the first guy that promises them nothing but sunny uplands.
You should read the article from 1956 called, When Prophecies Fail. It sums up your consistently inaccurate view of the seventh largest economy in the world.
California needs to keep running surpluses for a few decades.
Paper over a deficit here, a retroactive tax there, and delayed payments over there. And Voila! California has a 'surplus'! Smoke and mirrors isn't sustainable over the long term and the tax receipts are heavily inflated by large capital gains realized before the federal tax increase.
The Economist explains: How does a denial-of-service attack work?
The Economist explains
Money talks: A complacent market
Free exchange
Daily chart: Stated preferences
Graphic detail
The Economist explains: How hedge funds work
The Economist explains
Politics: Nick Clegg on being punished in the polls
Pregnancy and work: Supreme triangulation
Democracy in America
Have you listened to The Economist Radio on Facebook?
The Economist Radio is an on-demand social listening platform that allows you to listen, share and recommend The Economist audio content
Test your EQ
Take our weekly news quiz to stay on top of the headlines
In Other Words
Try our new audio app and website, providing reporting and analysis from our correspondents around the world every weekday
Want more from The Economist?
Visit The Economist e-store and you'll find a range of carefully selected products for business and pleasure, Economist books and diaries, and much more


text:
Consumer Products Manufacturing Reviews
"very motivating, career building experience" See all Reviews
prestige of the brand, forward thinking business development mindset. strong consumer brand still growing, proactive management team See all Reviews
"Enough with all the changes" See all Reviews
P&G employees are some of the most collaborative & intelligent people you can find. My coworkers help me to become a better employee and a better… See all Reviews
"Wipro Gallagher Solutions" See all Reviews
Very flexible depending on the department you work for. The work life balance is great. Great supportive supervisors. The departments work well… See all Reviews
"Very fun depending on management." See all Reviews
Easy easy work, fun people to work with, upbeat atmosphere, not a lot of responsibility, very flexible scheduling, great first job. See all Reviews
"This company has pushed me pass my limits in making sure that i am the best designer that i can be" See all Reviews
Nice people willing to help your career grow See all Reviews
"Great company" See all Reviews
They offer great opportunities for advancement See all Reviews
"It is a great company with great opportunity for growth. Also its a company that carries quality products." See all Reviews
Being able to work for a high fashion company with opportunity to grow within the company and learn new things. Also being able to take advantage of… See all Reviews
"I had a pleasant experience with the team members that I had the opportunity to work with." See all Reviews
Working with new technologies, overtime available when needed. See all Reviews
"I liked my co-workers but hours are not great" See all Reviews
fun people to work with,clothes are beautiful and easy to sell See all Reviews
"My experience @ Emerson was very rewarding and fulfilling both for my career and personal life." See all Reviews
Challenging opportunities, always something to do Strong company history Lots of resources to support you Friendly staff See all Reviews


text:
Based on 2 reviews
Help make it easier for other Avvo users to choose the right lawyer by sharing your experience with this attorney. It's fast, simple, and safe.
Lawyers: Use the Peer Endorsements section to provide input about other attorneys.
Patricia Fox represented me in a maintenance review. She was extremely thorough and organized in her approach and professional in her demeanor while also being personable and compassionate. Her deportment in the courtroom was above reproach. She was readily available and quick to respond to my questions and concerns. I heartily recommend her without hesitation.
I've found Ms. Fox to be an exceptional attorney who not only has a strong understanding of the law, but also has a strong understanding of the needs of the people she has been hired to represent.


text:
Royal Phuket City Hotel
No availability found through our partners. Please contact the business directly or check some of our recommended alternatives.
Photos of Royal Phuket City Hotel
Travelers also recommend:
TripAdvisor Reviews Royal Phuket City Hotel Phuket Town
Travel Blogs from Phuket Town
All Day at the Pool
... and it is good timing to recharge. L has decided that she is no longer so interested in cold weather travelling and prefers tropical vacations. She has said that she loves Thailand but my guess is she is loving resort vacations. It is very Important to keep this member of the family happy in order to have a chance to ever do this again. So I am happy she is enjoying herself and we are all feeling like we have caught our breath before the next leg of the trip starts ...
Bangkok is ace but it's nae bonnie
... people don't lie when they say when it rains here it's like a Monsoon and holy hell it was nuts! We had to climb about 300 stairs (felt like more) to get to the top of the temple fighting off the river of water that was flowing down the steps which put me in a bad mood within the first 2 minutes as my new vans are wrecked cos numbnut Emma said if you wear flip flops and show your feet in the temples the monks will think your ...
Day 7: GoKarting, Off Road Buggy's and home
... packed and checked out of my hotel. I'm going to miss Phuket because I had such a good time, although im excited to go home to! I've learnt so many new cultural and historical related things about Phuket and had an awesome time overall. I strongly recommend tour groups to visit Phuket because it's a fun packed island adventure!
It's a hard knock life.
... I found myself turning around countless times in the water to make sure a tidal wave wasn't coming. It was a terrible mind game to play with ones self but I almost couldn't help it. My condolences went out for the guy I met on Maya Bay a few days earlier. He was on the beach at the time and lost his girlfriend and family members in that tragic event. It's hard to imagine what he witnessed in those fleeting moments. From his perspective, he says that Buddha ...
Free ticket to the circus!
... you can't get there by car and the long tail boats couldn't either because the waves were too ********************** to believe, but I accepted the false information anyhow and moved to another location along Garbage Bay (what it should have been named).
I sat there not even a minute before I got bombarded by everyone and their mother to buy ridiculous things of all sorts. I think I said 'No' about 17 times before I started to get a little salty. I wanted to be like "NO! ...


text:
Geo Print Scuba Dress
Item# AS-022228_AS6342P
This sexy little sheath dress has all the right moves. A mod-inspired geometric print in the season's hot scuba material grabs attention the moment you walk in the room. Short sleeves, back and sides are in curve-loving ponte knit fabric to accentuate your shape. Faux leather trims the neckline and exposed silver-tone front zipper. Imported.
- Dry clean only
- Body: 96% Polyester, 4% Spandex; Trim: 90% Polyester, 10% Polyurethane
- 41.5 inches long from shoulder
Please Select a Size and Color
- Size
Special Offer
BUY one GET one 50% Off* Full Price Styles OnlyDetails
Buy 1 Full Price item and get the next Full Price item at 50% Off. Applies to lower priced item. Can not be combined with other offers.


text:
Hangin' out with David Strom: Exhibit by Windom artist at Nobles County Art Center
WORTHINGTON — Contrary to how the attached picture appears, David Strom has not lost his mind — at least not yet. He was just ready for a bit of frivolity before he got down to the serious business of hanging his paintings at the Nobles County Art Center in Worthington.
Get the full story
Subscribe or Log In
Are you a newspaper subscriber but you don't have a Digital Access account yet? Activate your account.
You will need your subscription account number and phone number. Not sure if you have an account? Email us or call (800) 274-5445 and we can help you.


text:
Diamondbacks reportedly in on James Shields
There has seemingly been a lack of interest in free agent starting pitcher James Shields this offseason, perhaps because of the right-hander's asking price. According to Ken Rosenthal of FOX Sports, that price may be coming down. Rosenthal reports that the Arizona Diamondbacks are in the mix to land Shields, which would seem to indicate…Read More


text:
Avery - Economy Reference Binder, Round Ring, Black - Various Sizes
by Avery | Item #: 289600 | Model #: AVE03401 |
Free shipping
- $ 3 58 - $ 5 88
Non-members pay 10% surcharge Join now!
Choose a Size: Please select a Size
- 1-1/2"
- 2"
- 3"
- Shipping
- Free shipping
- Enter ZIP Code for shipping options
- Estimated arrival
Delivery estimates, taxes, and fees are based on ZIP Code. Club Pickup orders are based on your club's current price and item availability on the day of payment.
A general-use binder at an affordable price. Suede-finish cover resists fingerprints. Two interior storage pockets for loose documents.
Assembled Country
Component Country
Ask & Answer
Shipping Information
Warranty InformationThis product is covered by the Sam's Club Member Satisfaction Guarantee.
There is no additional information available for this item.


text:
Prairie Nursery - Milkweed Plugs on sale - 15% off until April 21
mary_littlerockar(8a-7b mid Arkansas)April 9, 2014
I have received an email regarding the sale of milkweed plugs at Prairie Nursery. For those who would like to get a jump start on the season, several varieties of Milkweed plugs are available and currently on sale.
I can't remember if I've ever used this nursery so proceed with the usual caution if using a new on-line vendor. Perhaps there is someone on the forum who could comment if they've had experience with Prairie Nursery.
Just wanted to pass along this information.
Here is a link that might be useful: Prairie Nursery - Milkweed Plug sale


text:
I just received an order that I had just placed yesterday. Your service is always fast but this was unbelievable. Thank you for the great service.
More Testimonials »
Amazing Crayon Drawing with Lee Hammond
North Light
From $18.39
Artist Journal Workshop
Artist Trading Card Workshop
From $18.04
Calligraphy Magic
Collage Discovery Workshop
From $19.07
Collage Unleashed
From $17.58
Colored Pencil Portraits Step by Step
From $19.53
Colored Pencil Solution Book
Up to 26% Off
Creating Textures in Colored Pencil 15th...
Doodle, Draw, Journal
From $13.59
Drawing Realistic Pets From Photographs
From $15.29
Drawing for the Absolute Beginner
Fairies, Gnomes, & Trolls: Create a...
Fill Your Oil Painting with Light & Color
From $15.69
Keys to Painting Fur & Feathers
From $16.74
Lee Hammond's Big Book of Drawing
From $19.27
Lifelike Drawing with Lee Hammond
Mixed Media Storytelling Workbook
Mixed Media Techniques for Art Journaling
Painting Songbirds
Painting with Brenda Harris, Volume 3...
Pretty Little Things: Collage Jewelry...
Secrets to Drawing Realistic Faces
From $18.82
The Artist's Guide to Drawing Realistic...
The Chinese Brush Painting Bible
From $11.99
The Drawing Bible
Up to 32% Off
The Watercolor Bible
The Watercolorist's Essential Notebook...
Wide Open
stART Journaling


text:
|Blog Posts
When it comes to sex, everyone is different. Something that pushes all the buttons for one person could be a big turn-off for someone else.
Unless you're a mind reader, you'll need to tell your partner what you enjoy. By communicating with your partner, you can find out what you both like and how to make your lovemaking even more enjoyable.
Talking about sex can also be a turn-on, and add to the experience. It can give you the chance to introduce new elements to your sex life, such as new sexual positions, sex toys or even making love more often or at different times.
You'll also find it easier if you have any troubles or problems, because you'll be more open and relaxed with each other. If you can start talking about sex, you'll soon find that you are trying new things, working through any problems and getting the maximum pleasure from your sex life.
Talking about sex might be difficult if you've never broached the subject before, but there are ways to make it easier. A good way to bring up the subject is to use something you can both focus on. A book, magazine article or TV program can be an easy way to get talking.
Ensure that the communication continues when you have sex. Ask questions about what feels good, and when your partner does something that you enjoy, make sure they know by telling them. Don't be afraid to take their hand and demonstrate how you like to be touched. Encourage them to do the same. You won't automatically know what they like, so don't be ashamed to get them to show you.
Be honest about how you feel. Focus on what they do that feels good rather than what you don't like, and don't say that something is good just for the sake of it.
If you're normally quiet during sex, make sure you both know that you're going to be talking. If you've been silent with your partner about sex in the past, take your time. You'll soon build the confidence to talk more and more about what you want from your sexual relationship.
You'll find out things about each other you never knew, and improve not only your sex life, but other areas of your relationship as well.
Write a comment:


text:
Ask our consultant
Upcoming events
Register here to add your business proposal
- UAE-Lithuania Business Forum discusses joint cooperation, investment opportunities 2015-02-12Enterprise Lithuania
- Lithuania - United Kingdom bilateral trade 2014-07-02Enterprise Lithuania
Lithuanian Exporters Database
SIDVIJA JSCPakruojo Raj., LithuaniaBusiness line: Work clothes producing
LTD "Sidvija" was established 2001 m. Our company specializes in sewing medical clothes, food industry workwear and other work outfits. Customers can submit their...Updated: 2014-12-170 0 Recommendations:
Mirosta JSCPlungė, LithuaniaBusiness line: High quality houses / furniture / stairs
LHM is a group of companies working for more than 10 years for Scandinavian, mainly Norwegian market. Our core products are high quality houses, furniture, stairs. All only from massive wood....Updated: 2014-11-240 0 Recommendations:
ART BETONAS.LTŠalčininkai, LithuaniaBusiness line: Concrete products
Sculptural masterful ''Art betonas.lt''
The workshop makes high-quality art products for external, internal and garden design of structures, such as fountains,...Updated: 2014-12-020 0 Recommendations:
GENERGA JSCKaunas, LithuaniaBusiness line: Manufacture of power generators
GENERGA - diesel and petrol power generators (2-1000 kVA) manufacturer from Lithuania.
High quality components from EU and Japan only (Honda, Volvo Penta, Perkins, NSM, Linz...Updated: 2014-12-010 0 Recommendations:
Sargasas JSCVilnius, LithuaniaBusiness line: Metal processing
UAB "Sargasas" the enterprise of Lithuania is the enterprise of metal processing, operating since 2005. The nomenclature of milled and turned parts consists of more than 2500...Updated: 2014-11-260 0 Recommendations:
Baltic Line JSCVilnius, LithuaniaBusiness line: Transport and logistics
JSC Baltic Line is a company engaged in local and international goods transport and forwarding, and providing integrated logistics services. The company's goods transport network covers...Updated: 2014-11-240 0 Recommendations:


text:
1999 Mulderbosch Sauvignon Blanc30 Ratings
30 Ratings
1999 Mulderbosch Sauvignon Blanc
Wine Details
Winemaker's Notes
(From «nv» Vintage) Clear, light lime green color. A tropical nose packed with guava, green fig, granadilla and a hint of floral - yet still maintaining a complex character of nettle and freshly cut grass. The mouth-filling ripe fruit is supported by crisp acid. This wine screams one thing: "Give me more !!!"
Shipping Information
Free shipping with a purchase of 12 bottles or more.


text:
Napa High School Alumni
Elena Murgoska
Class of 2005
Irene Shin
Class of 1982
Vickie Gurry
Class of 1974
Sam Lavrar
Class of 1972
Alumni from Napa can use this site to get in touch with old friends from their high school in CA. We also encourage you to keep up to date on news and reconnect with lost friends. You can also find out what other graduates are doing now, share memories with other alumn, upload pictures from Napa and find other alumni.


text:
Whaleyville is a populated place LOCATED WITHIN the City of Suffolk. In turn, the City of Suffolk is located within Suffolk (city) County.
Whaleyville is located at latitude 36.588 and longitude -76.685. The elevation of Whaleyville is 66 feet above mean sea level.
Since Whaleyville is located within the City of Suffolk, all of the census and demographic data for residents of Whaleyville are included as part of the information reported for City of Suffolk in the "Data" tab above.
In similar fashion, ALL OF THE NAVIGATION TABS ABOVE ARE FOR THE City of Suffolk Community Profile.
Suffolk (city) County: Cities & Towns | ZIP Codes | Features (airports, churches, hospitals, etc.)
BIG Map |
Driving Directions |
Data Source - USGS GNIS FID: 1500306
BOUNDARY MAPS: City of Suffolk | | Suffolk (city) County


text:
A Senate bill would require instruction of cursive handwriting and memorization of multiplication tables.
The so-called Greatest Show on Earth will soon be without elephants.
The federal Centers for Medicare & Medicaid Services (CMS) approved a health care expansion waiver for New Hampshire.
TIME Magazine recently outlined five things that you should be aware of when you use your personal e-mail while on the job.
The City of Lebanon has posted a weight limit of 6 tons on various city roads.
Pod-based coffee machines that make individual cups of java are now used in one out of three American homes.
The future of health care in America is on the table this morning in the Supreme Court.
New Hampshire State Police say a tractor-trailer was driving too fast for the slick conditions when it crashed early Wednesday morning.
Police in Farmington are on the lookout for upstanding citizens and good behavior.
The Department of Homeland Security won't run out of money anytime soon.
What's a good way to improve someone's health? Some researchers say add a tax!
More than half of the animals rescued from a home in Eden, Vermont this week are now at animal shelters in Vermont and New Hampshire.
The early birds who have already filed their tax returns are apparently catching a whole lot of worms.
The Bureau of Alcohol, Tobacco, Firearms, and Explosives (ATF) announced they want to ban certain types of ammunition.
We are in the middle of tax season and this year there is some good news as you gather all the documents needed to file your return.
The FCC has approved new rules to uphold net neutrality on Thursday.
A stunning revelation from the head of the Federal Bureau of Investigations (FBI) about rise of radical and violent extremism in the U.S.
A new study suggests that marijuana might be even safer than researches once thought.
Meteorologist Michael Page explains why parts of our area were the coldest in the nation yesterday.
A new study suggests avoiding peanuts for infants could make food allergies worse later in life.
A new report from Gallup found that the nationwide uninsured rate dropped 3.5 percent from last year, from 17.3 percent to 13.8 percent.
Dartmouth-Hitchcock is investing nearly half a million dollars to fly it's helicopters in poor weather conditions. Meteorologist Michael Page takes to the air to see how it works.
A new poll suggests that parents should be required to vaccinate their kids.
Al-Shabaab released a video calling for attacks on malls in Canada, the United Kingdom, and United States.
New Hampshire Governor Maggie Hassan announced that more than 35,000 people have enrolled in the New Hampshire Health Protection Program.
A preview of Meteorologist Michael Page's story on how Dartmouth-Hitchcock is investing in new technology to keep its chopper's flying in bad weather.
According to a new study, maybe you should wear your sunglasses and sunscreen at night.
The deadline for those wanting to enroll in the Affordable Care Act has been extended.
A 2008 Dartmouth graduate will appear on Shark Tank, a show featuring budding entrepreneurs Friday night.
After 126 long days at the picket line, FairPoint workers finally have a potential deal to get back to work.
A new study suggests a delay in starting school for summer-born or premature children is linked with poor academic performance.
FairPoint announced the company and workers have reached a tentative deal Thursday.
A new report ranked the well-being of states and communities across the country.
Walmart announced Thursday they are giving approximately 500,000 employees a raise.
The New Hampshire Fish & Game is looking to identify a driver accused of hitting and injuring two dogs on Sunday.
The New Hampshire Attorney General's Office is encouraging all Anthem members to sign up for credit protection services.
Florida scientists are calling it a "remarkable new advance" against HIV, the virus that causes AIDS.
The National Toy Hall of Fame is expanding to include a world Video Game Hall of Fame.
As the world drinks more of it, don't be surprised to see your coffee prices spike over the next few years.
Millions of tax returns are being filed across the country and billions of dollars are being returned to taxpayers in refunds.
The 100th block of Loomis Street was closed and without water for much of Sunday.
New Hampshire's Department of Safety is urging people to protect themselves.
The deadline is Sunday, February 15th to qualify for health insurance.
With another blizzard looming, crews from both New York and Vermont started removing snow in Massachusetts this week.
Kidde is recalling about 4.6 million fire extinguishers in the United States.
With extremely cold temperatures expected to affect the region over the next few days, here are some ways to stay safe.
There's no denying the bond that can develop between people and their pets.
The deadline is approaching if you want to enroll for health care under the Affordable Care Act.
Three women are dead after a serious car crash in New Hampshire on Thursday night.
The recent stretch of winter weather that has hit the region has put a strain on winter maintenance budgets.


text:
Where's the beef: A shift to white meats will cut into growth, but demand will remain steady
IBISWorld's Beef Cattle Production market research report is a comprehensive guide to market size and growth prospects. Our industry reports offer strategic industry analysis of the factors influencing companies, including new product developments, economic, lifestyle and demographic influences, distribution and supply chain factors and pricing issues. Full analysis accompanies our data forecasts to illustrate how the market responds to emerging industry trends.
For decades, Americans' love of steaks and burgers maintained beef as the most consumed meat in the United States. However, in recent years, consumption of beef has declined due to the health risks associated with red meat. In the coming years, this trend is set to continue, as consumers purchase more lean, white meats, which will stifle growth in industry revenue... purchase to read more
Compared with the rest of the farming sector, Beef Cattle Production can require a substantial amount of investment capital, especially in the feedlot segment. The basic equipment requirements for feedlot operations are loader tractors, feed trucks, scales, corrals and fencing for lots, feed and water troughs, and grain silos for feed storage. Larger feedlots invest in specialized machinery and newer technology, such as computerized feeding and cattle management systems. Cattle ranches are much less automated and require a lower investment in capital. Cattle in ranches typically graze in large paddocks, lowering the costs of animal shelter, housing and maintenance.
As cattle ranches become more advanced, their costs rise but they also allow farmers to use less labor... purchase to read more
This industry includes farms and ranches that primarily engage in raising cattle (including cattle for dairy herd replacements), or feeding cattle for fattening to prepare them for consumption. The industry also comprises cattle feedlot operations, which produce high-quality beef.
Industry Definition
Main Activities
Similar Industries
Additional Resources
Executive Summary
Key External Drivers
Current Performance
Industry Outlook
Industry Life Cycle
Supply Chain
Products & Services
Major Markets
Business Locations
Competitive Landscape
Market Share Concentration
Key Success Factors
Cost Structure Benchmarks
Barriers to Entry
Capital Intensity
Industry Data
Annual Change
Key Ratios


text:
Please help us! 3 Ways You Can Help
Vote Smart Just The Facts
"Experts nearly all recommend Vote Smart."
"Vote Smart is a bright light in an often desultory civic culture."
- Bill Moyers
"We think so highly of Vote Smart that we are distributing their materials to all of our affiliates."
Colin O'Neill's Biography
Contact Information
Full Name:Colin Delaney O'Neill
- BA, Political Science, University of Southern Maine, 2012
- Intern, Congressman Tom Allen, former
- Intern, Congresswoman Chellie Pingree, former
- Intern, Senator Susan Collins, former
- Candidate, Maine House of Representatives, District 100, 2012
- Candidate, Maine House of Representatives, District 100, 2010
- No caucus information on file.
- No professional experience on file.
- No organizational membership information on file.


text:
Hi I am Jessica! I'm 29 years old and a mom to the coolest 3 year old around. I think I am a pretty cool person and I generally get along with everyone. People often tell me I am funny and fun to be around. I mean I was voted class clown back in high school a million years ago. I have a pretty interesting story to tell about my life (at least I think it's interesting) I will tell ya if you want to know. Well I was born on the first day of May....I'm just kidding, ask if you want to know!
Join OkCupid
Find better matches with our advanced
Find better matches with our advanced
matching system
—% Match
—% Enemy
31 • Flint, MI • Woman
I'm looking for
- Men
- Ages 27–35
- Near me
- Who are single
- For new friends
My details
- Last online
- Jan 12, 2013
- Orientation
- Straight
- Ethnicity
- White
- Height
- 5′ 5″ (1.65m)
- Body type
- Average
- Diet
- —
- Smokes
- Sometimes
- Drinks
- Not at all
- Drugs
- Never
- Religion
- —
- Sign
- Taurus
- Education
- —
- Job
- —
- Income
- —
- Status
- Single
- Type
- —
- Offspring
- Has a kid, and might want more
- Pets
- —
- Speaks
- English
Similar Users
My self-summary
Write a little about yourself. Just a paragraph will do.
What I'm doing with my life
Don't overthink this one; tell us what you're doing day-to-day.
Well I am a Certified Alcohol and Drug Counselor and have worked at a substance abuse treatment center for the last 5 YEARS. Most importantly tho I am a mommy to my 3 year old son.
I'm really good at
Go on, brag a little (or a lot). We won't judge.
Helping others, my job and being a good friend.
The first things people usually notice about me
I'm an empty essay… fill me out!
My eyes and my smile
Favorite books, movies, shows, music, and food
Help your potential matches find common interests.
I don't read a whole lot but when I do its usually some trashy kind of story with lots of drama.....maybe I like that cause I can always sit back and say "at leastbim not going through all this". Movies I love the Twighlight series and a bunch of other chick flicks.
The six things I could never do without
Think outside the box. Sometimes the little things can say a lot.
My son
My relationship with God
My family
My dog
Diet coke
Love and respect for myself
My relationship with God
My family
My dog
Diet coke
Love and respect for myself
I spend a lot of time thinking about
Global warming, lunch, or your next vacation… it's all fair game.
What God has planned for me now????
On a typical Friday night I am
Netflix and takeout, or getting your party on — how do you let loose?
Sitting at home with my son wishing someone would come hang out
The most private thing I'm willing to admit
I'm an empty essay… fill me out!
I don't have many secrets.....
You should message me if
Offer a few tips to help matches win you over.
Your awesome, serious and not just playing games, and want to get to know me!
Connect your existing OkCupid account
Sign in
Welcome Back!
Restore your account to continue meeting new people.
Reset your password
We'll email you a link to reset it.
Email sent!
An email is on its way to . If you don't see it, try checking your Spam folder.


text:
Vanilla Dome (my remix)
Credits & Info
- Date
- 03/14/2011
- File Info
- Loop
- 2 min 24 sec
- Score
- 3.90 / 5.00
Related Content
You might also enjoy:
Licensing Terms
- Attribution:
- You must give credit to the artist.
- Noncommercial:
- You may not use this work for commercial purposes unless you make specific arrangements with the artist.
- Share Alike:
- If you alter, transform, or build upon this image, you may distribute the resulting creation only under a license identical to this one.
- Score:
- Rated 3.90 / 5 stars
- Plays & Downloads:
- 600 Plays | 42 Downloads
- Share Links:
- Genres:
- Electronic - Video Game
- None
Author Comments
Rated 4 / 5 stars
Pretty good... but...
I really like this, but I feel the little "sparkle" sound (I hope you understand what I mean) is a little overpowering. If you were to turn it down a little, this would be perfect.
I know what you mean. And as I mentioned in the description, I no longer have the files to edit these works, so unless I create it from scratch, what you hear is what you get, lol. Thanks for the input though. My older works had tendencies to be too bright (so parts like that I would make too loud), so your comment is pretty understandable.
Rated 5 / 5 stars
Yes, yes, and yes.
Mario brothers for the win!!!
This is the kinda stuff I did when I got bored. SMB are win: I totally agree!


text:
Flat Roof Coating
I have a 10 year old house I bought 4 years ago. The year I bought it I had the roof coated with some aluminum looking stuff. It's a basic spanish style house that has two flat roof sections. The roof needs recoating. A couple of questions.
Would it be a good idea to power wash the roof before coating it. And second, what is the best coating for the money for me to use. This is going to be a DIY project.
I wouldn't pressure wash it if it's a mineral surfaced, (rool roofing) covering but rather take a garden hose with a pressure nozzle along with a roofers stiff broom and scrub/rinse away any areas where dirt is stuck, let dry, and coat twice with an elasomeric roof coating. Make sure before coating that you have all loose debris picked up, mastic around any protrusions such as vents if needed, and tighten up any nailed areas if loose. You also want it to be at least 50 degrees for 24 hours cure time on most coatings and of course the warmer it is, the easier it is to work the product.


text:
Doorbell mystery
My in-laws have a multi-chime electronic doorbell about 15 years old. Recently, it has taken it upon itself to ring randomly.
Door button has been replaced and wiring appears to be sound. I don't believe there's a short between the chime and the button because it only rings once; were it a short, it would ring continuously (I tested that).
Is it more likely to be the transformer, the circuit board, or something else?
Not likely the transformer. If it has a circuit board that could be the problem.
Still could be a problem with the wiring. Disconnect the button connection at the chime and leave it off for several days. See if it stops ringing. If there are more than one button do them one at a time or do them all and then start putting them back one at a time.


text:
Cory Montieth's death (he was found dead in a hotel in Vancouver on July 13 due to high dose of heroin and alcohol) has left his girlfriend and alleged fiancé Lea Michelle in deep distress. T
he Glee star (plays Rachel Berry) is shattered by the loss of her love of life and her sadness is immeasurable.
To cope up with the sudden death of Monteith (he played Finn Hudson on the show)the makers of Glee have postponed the shooting and season premiere by one week.
In an interview to TV line, the show producer, Ryan Murphy said "Lea is obviously very grief-stricken. It's been a very difficult thing for all of us, including Lea, to love someone who is an addict. It's something all of us have been dealing with for many months."
He even revealed the present state of mind of Lea that she has shown unbelievable strength in the trying times. "She is one of the strongest people I know," he said.
We take a look at the top 5 sad songs sung by Lea Michelle on the popular show Glee.
Jar of Hearts
My Man
What I did for love
Without you I will never be the same


text:
Turns a raw and crunchy Markdown file into nice and smooth output
Asynchronously convert a Markdown file into HTML. WOW!
You can specify either the contents of a file, or, the path to a file to read.
var roaster = require"roaster";var fs = require"fs";var options = {} roaster"./markdown.md" options fswriteFileSync"./markdown.html" contents "utf8";;
The second parameter,
options, is optional. Any options defined
here are passed to the dependent libraries for use in their own systems.
If you pass
options.isFile, the first parameter is assumed to be a file path.
By default, this is
false, which means that the first parameter is an
actual string of Markdown.
Libraries used
- marked for Markdown conversion
- emoji-images for emoji conversion
- task-lists for GFM style task lists conversion


text:
The Mequon-Thiensville School District is crowdsourcing the creation of its new logo with a community-wide contest.
According to a district release, all community members, including past and current students, can enter designs. Contestants must live in or have attended the Mequon-Thiensville district, and are allowed to submit multiple entries.
The winning look will go on the district website, letterhead, and be used in future branding.
"The logo currently being used the by Mequon-Thiensville School District has become outdated and we seek an updated logo that builds on the fine tradition of the school district," Superintendent Demond Means said in the release. "We are very excited to see the submitted designs."
The district is accepting entries through Feb. 8 at www.mtlogocontest.com and will announce a winner in early March.
This site uses Facebook comments to make it easier for you to contribute. If you see a comment you would like to flag for spam or abuse, click the "x" in the upper right of it. By posting, you agree to our Terms of Use.
E-mail Newsletter
Your link to the biggest stories in the suburbs delivered Thursday mornings.
Enter your e-mail address above and click "Sign Up Now!" to begin receiving your e-mail newsletter Get the Newsletter!
More from News and Features
- Mequon-Thiensville Police Report: March 26, 2015
- North Shore Police Reports: March 26, 2015
- Mequon-Thiensville Police Report: March 19, 2015
- Candidates for Mequon City Council focus on commercial, residential development
- North Shore Police Reports: March 19, 2015
- Sarah Chudnow Community offers a variety of programming for April
- Mindful meditation comes to Mequon
- Homestead High School reverses decision to restructure final exams
- Mequon-Thiensville Police Report: March 12, 2015
- North Shore Police Reports: March 12, 2015


text:
Mr Hudson - Step Into The Shadows
Artist: Mr Hudson
Album: None (Promo Single)
Avg Rating: 3.0 ( 1 votes )
If you've ever been to a shadier part of town, you know that you can't find anything good for you there. You may think you've found a girl there who could change your world, but more than likely the potential relationship is for the worst. Mr Hudson is all too familiar with such a tale. On his latest single, Step Into The Shadows, the G.O.O.D. Music singer has an encounter with the closest thing to a vampire that a human can come to, except she is after more than just his blood. As soon as he steps into her "shadow," the dense piano beat turns even darker with actor Idris Elba speaking as Mr Hudson's tormented inner self. I can already see this song being a big hit for a dramatic play. If it never makes it to Broadway, though, you can still buy the single on iTunes on May 13.
Written by Bryan H on 05/9/14
Submit your Rating
G.O.O.D. Music/Universal
First DJ Booth Appearance:
"Paranoid (Remix) ft. Kanye West & Mr. Hudson" (2008)
Total DJ Booth Features:
5 Songs
You Might Like...
Commentsblog comments powered by Disqus
DJBooth TV
Discover the best new songs, videos, and albums added to the Booth.


text:
Encontrar uma cópia on-line
Links para este item
bvbr.bib-bvb.de Klappentext
Encontrar uma cópia na biblioteca
Encontrando bibliotecas que possuem este item...
|Criticism, interpretation, etc
|Pessoa Denominada:
|Oscar Wilde; Oscar Wilde; Oscar Wilde; Oscar Wilde; Oscar Wilde; Oscar Wilde
|Tipo de Material:
|Recurso Internet
|Tipo de Documento:
|Livro, Recurso Internet
|Todos os Autores / Contribuintes:
Jarlath Killeen
|1403948941 9781403948946
|Número OCLC:
|xi, 228 pages ; 23 cm.
|Child and man : the development of a Catholic mind --
Faith and reason : the Bible, the Catholic church and Wilde's scandalous writings --
Body and soul : nature, the host and folklore in The picture of Dorian Gray --
Religion and politics : Wilde's social philosophy --
Art and life : the politics of ritualism in The importance of being Earnest --
Realism and romance : between Protestantism and Catholicism in Wilde's final writings.
|Título da Série:
|Palgrave studies in nineteenth-century writing and culture.
|Jarlath Killeen.
|Mais informações:
"This energetic and original book examines in detail the relationship between faith, theology, religious history and national politics in the major writings of Oscar Wilde. It focuses in particular on Wilde's lifelong attraction to Catholicism, an attraction originating in his time spent as a boy in the west of Ireland. Killeen also closely examines the influence of Wilde's Protestant heritage on his work: his antagonism towards this heritage is closely related to the narrative modes he chose to work in, and the aesthetic philosophy he espoused. Overall, the book demonstrates how Wilde combined his religious leanings with a reconfiguration of Nationalism, while an Irish 'exile' in London. For Wilde, Catholicism and Irish Nationalism were interdependent projects that operated as the fields of force energising his writing. Providing an entirely fresh critical perspective on his writing (including The Picture of Dorian Gray, The Importance of Being Earnest), this new study will be of interest to all students and scholars of Wilde."--Jacket.
Críticas contribuídas por usuários
Ítens Similares
Assuntos Relacionados:(20)
- Wilde, Oscar, -- 1854-1900 -- Religion.
- Christianity and literature -- Ireland -- History -- 19th century.
- Literature and folklore -- Ireland -- History -- 19th century.
- Wilde, Oscar, -- 1854-1900 -- Criticism and interpretation.
- Wilde, Oscar, -- 1854-1900 -- Homes and haunts -- Ireland.
- Wilde, Oscar, -- 1854-1900 -- Knowledge -- Folklore.
- Catholics -- Ireland -- Intellectual life.
- Christianity in literature.
- Wilde, Oscar, -- 1854-1900
- Catholics -- Intellectual life.
- Christianity and literature.
- Folklore.
- Homes.
- Literature and folklore.
- Religion.
- Ireland.
- Wilde, Oscar.
- Irlandbild.
- Katholizismus (Motiv)
- Volkskultur (Motiv)
Listas de usuários com este item (2)
- Things to Check Out(70 ítens)
por jlt255 atualizado 2012-05-27
- Oscar Wilde(477 ítens)
por chengannchitracy atualizado 2010-01-14